


DPTIP

Cat. No.:	HY-131002	
CAS No.:	351353-48-5	
Molecular Formula:	C ₂₁ H ₁₈ N ₂ O ₃ S	
Molecular Weight:	378.44	
Target:	Phospholipase	
Pathway:	Metabolic Enzyme/Protease	
Storage:	Powder	-20°C 3 years
	In solvent	-80°C 6 months
		-20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (660.61 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
			1 mM	2.6424 mL	13.2121 mL	26.4243 mL
			5 mM	0.5285 mL	2.6424 mL	5.2849 mL
			10 mM	0.2642 mL	1.3212 mL	2.6424 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.08 mg/mL (5.50 mM); Suspended solution; Need ultrasonic					

BIOLOGICAL ACTIVITY

Description	DPTIP is a potent brain penetrant neutral sphingomyelinase 2 (N-SMase 2) inhibitor (exosome inhibitor), with an IC ₅₀ of 30 nM ^{[1][2]} .	
In Vitro	DPTIP blocks EV secretion in a dose dependent manner (0.03-30 μM), and at 30 μM, this compound could decrease exosome release by 50% in astrocytes ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	DPTIP potently (10 mg/kg IP) inhibits IL-1β-induced astrocyte-derived EV release ^[1] .	
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
Animal Model:	Mice ^[1] .	

Dosage:	10 mg/kg.
Administration:	IP 0.5 h prior to IL-1 β striatal injection.
Result:	Brain concentrations of DPTIP are above its IC ₅₀ for nSMase2 inhibition for at least 4 h after compound administration. The number of astrocyte-derived EVs was reduced by 51 \pm 13% 2 h post IL-1 β administration.

REFERENCES

[1]. Camilo Rojas, et al. DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation. *Sci Rep.* 2018 Dec 7;8(1):17715.

[2]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. *J Enzyme Inhib Med Chem.* 2020 Dec;35(1):1322-1330.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA